NorthCrest Asset Manangement LLC Acquires New Position in DaVita Inc. (NYSE:DVA)

NorthCrest Asset Manangement LLC acquired a new stake in DaVita Inc. (NYSE:DVA - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 6,464 shares of the company's stock, valued at approximately $989,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Wellington Management Group LLP increased its holdings in DaVita by 9.1% during the 4th quarter. Wellington Management Group LLP now owns 2,711 shares of the company's stock valued at $405,000 after acquiring an additional 227 shares in the last quarter. Hussman Strategic Advisors Inc. increased its holdings in DaVita by 200.0% during the 4th quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company's stock valued at $3,769,000 after acquiring an additional 16,800 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in DaVita during the 4th quarter valued at about $597,000. Convergence Investment Partners LLC increased its holdings in DaVita by 33.2% during the 4th quarter. Convergence Investment Partners LLC now owns 11,389 shares of the company's stock valued at $1,703,000 after acquiring an additional 2,836 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in DaVita during the 4th quarter valued at about $5,636,000. Institutional investors and hedge funds own 90.12% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on DVA shares. Truist Financial dropped their target price on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a report on Monday, May 19th. Barclays lifted their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. Finally, Cowen reiterated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $164.50.

DaVita Price Performance

DaVita stock opened at $135.93 on Friday. DaVita Inc. has a 1 year low of $131.76 and a 1 year high of $179.60. The firm has a 50 day moving average price of $141.36 and a 200 day moving average price of $151.08. The company has a market cap of $10.26 billion, a price-to-earnings ratio of 12.66, a PEG ratio of 1.07 and a beta of 1.11. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The firm had revenue of $3.22 billion during the quarter, compared to the consensus estimate of $3.22 billion. During the same period in the previous year, the firm earned $2.26 earnings per share. DaVita's revenue was up 5.0% compared to the same quarter last year. Sell-side analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.